Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Changes in advanced oxidation protein products, advanced glycation end products, and s-nitrosylated proteins, in patients affected by polycythemia vera and essential thrombocythemia.

Musolino C, Allegra A, Saija A, Alonci A, Russo S, Spatari G, Penna G, Gerace D, Cristani M, David A, Saitta S, Gangemi S.

Clin Biochem. 2012 Nov;45(16-17):1439-43. doi: 10.1016/j.clinbiochem.2012.07.100. Epub 2012 Jul 28.

PMID:
22850610
2.

Increased serum levels of neutrophil gelatinase-associated lipocalin in patients with essential thrombocythemia and polycythemia vera.

Allegra A, Alonci A, Bellomo G, Campo S, Cannavò A, Penna G, Russo S, Centorrino R, Gerace D, Petrungaro A, Musolino C.

Leuk Lymphoma. 2011 Jan;52(1):101-7. doi: 10.3109/10428194.2010.531413. Epub 2010 Dec 6.

PMID:
21133718
3.

Circulating endothelial cells in essential thrombocythemia and polycythemia vera: correlation with JAK2-V617F mutational status, angiogenic factors and coagulation activation markers.

Treliński J, Wierzbowska A, Krawczyńska A, Sakowicz A, Pietrucha T, Smolewski P, Robak T, Chojnowski K.

Int J Hematol. 2010 Jun;91(5):792-8. doi: 10.1007/s12185-010-0596-7. Epub 2010 May 15.

PMID:
20473593
4.

Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).

Michiels JJ, Bernema Z, Van Bockstaele D, De Raeve H, Schroyens W.

Pathol Biol (Paris). 2007 Mar;55(2):92-104. Epub 2006 Aug 21. Review.

PMID:
16919893
5.

Megakaryopoiesis and platelet function in polycythemia vera and essential thrombocythemia patients with JAK2 V617F mutation.

Hattori N, Fukuchi K, Nakashima H, Maeda T, Adachi D, Saito B, Yanagisawa K, Matsuda I, Nakamaki T, Gomi K, Tomoyasu S.

Int J Hematol. 2008 Sep;88(2):181-8. doi: 10.1007/s12185-008-0129-9. Epub 2008 Jul 10.

PMID:
18612778
6.

Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia.

Teofili L, Giona F, Martini M, Cenci T, Guidi F, Torti L, Palumbo G, Amendola A, Foà R, Larocca LM.

J Clin Oncol. 2007 Mar 20;25(9):1048-53.

PMID:
17369568
7.
9.

Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications.

Michiels JJ, Berneman Z, Van Bockstaele D, van der Planken M, De Raeve H, Schroyens W.

Semin Thromb Hemost. 2006 Apr;32(3):174-207. Review.

PMID:
16673274
10.

JAK2V617F mutation and hydroxyurea treatment as determinants of immature platelet parameters in essential thrombocythemia and polycythemia vera patients.

Panova-Noeva M, Marchetti M, Buoro S, Russo L, Leuzzi A, Finazzi G, Rambaldi A, Ottomano C, Ten Cate H, Falanga A.

Blood. 2011 Sep 1;118(9):2599-601. doi: 10.1182/blood-2011-02-339655. Epub 2011 Jul 12.

11.

Dkk3 levels in patients with myeloproliferative neoplasms.

Medinger M, Muesser P, Girsberger S, Skoda R, Tzankov A, Buser A, Passweg J, Tsakiris DΑ.

Thromb Res. 2014 Feb;133(2):218-21. doi: 10.1016/j.thromres.2013.11.003. Epub 2013 Nov 14.

PMID:
24309205
12.

JAK2V617F allele burden is associated with thrombotic mechanisms activation in polycythemia vera and essential thrombocythemia patients.

Coucelo M, Caetano G, Sevivas T, Almeida Santos S, Fidalgo T, Bento C, Fortuna M, Duarte M, Menezes C, Ribeiro ML.

Int J Hematol. 2014 Jan;99(1):32-40. doi: 10.1007/s12185-013-1475-9. Epub 2013 Nov 26.

PMID:
24277659
13.

Serum hepcidin and growth differentiation factor-15 (GDF-15) levels in polycythemia vera and essential thrombocythemia.

Tarkun P, Mehtap O, Atesoğlu EB, Geduk A, Musul MM, Hacihanefioglu A.

Eur J Haematol. 2013 Sep;91(3):228-35. doi: 10.1111/ejh.12150. Epub 2013 Jun 28.

PMID:
23731455
14.

Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia.

Vannucchi AM, Antonioli E, Guglielmelli P, Rambaldi A, Barosi G, Marchioli R, Marfisi RM, Finazzi G, Guerini V, Fabris F, Randi ML, De Stefano V, Caberlon S, Tafuri A, Ruggeri M, Specchia G, Liso V, Rossi E, Pogliani E, Gugliotta L, Bosi A, Barbui T.

Blood. 2007 Aug 1;110(3):840-6. Epub 2007 Mar 22.

15.

Proteomic study of the impact of the JAK2-V617F mutation on the phenotype of essential thrombocythemia.

Mossuz P, Arlotto M, Hermouet S, Bouamrani A, Lippert E, Girodon F, Dobo I, Vincent P, Cahn JY, Berger F.

Exp Hematol. 2008 Dec;36(12):1642-7. doi: 10.1016/j.exphem.2008.07.013. Epub 2008 Oct 5.

PMID:
18838204
16.

Discriminating between essential thrombocythemia and masked polycythemia vera in JAK2 mutated patients.

Barbui T, Thiele J, Carobbio A, Guglielmelli P, Rambaldi A, Vannucchi AM, Tefferi A.

Am J Hematol. 2014 Jun;89(6):588-90. doi: 10.1002/ajh.23694. Epub 2014 Mar 3.

17.

[Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].

Iványi JL, Marton E, Plander M.

Orv Hetil. 2011 Nov 6;152(45):1795-803. doi: 10.1556/OH.2011.29226. Hungarian.

PMID:
22011365
18.

Src tyrosine kinase preactivation is associated with platelet hypersensitivity in essential thrombocythemia and polycythemia vera.

Randi ML, Brunati AM, Scapin M, Frasson M, Deana R, Magrin E, Fabris F, Donella-Deana A.

Blood. 2010 Jan 21;115(3):667-76. doi: 10.1182/blood-2008-12-196535. Epub 2009 Nov 12.

19.

Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera.

Marchetti M, Castoldi E, Spronk HM, van Oerle R, Balducci D, Barbui T, Rosing J, Ten Cate H, Falanga A.

Blood. 2008 Nov 15;112(10):4061-8. doi: 10.1182/blood-2008-06-164087. Epub 2008 Sep 3.

20.

Evaluation of interleukin-23 plasma levels in patients with polycythemia vera and essential thrombocythemia.

Gangemi S, Allegra A, Pace E, Alonci A, Ferraro M, Petrungaro A, Saitta S, Gerace D, Russo S, Penna G, Musolino C.

Cell Immunol. 2012 Jul-Aug;278(1-2):91-4. doi: 10.1016/j.cellimm.2012.07.003. Epub 2012 Aug 1.

PMID:
23121980

Supplemental Content

Support Center